Daily Stock Analysis, AKER, Akers Biosciences Inc, priceseries

Akers Biosciences Inc. Daily Stock Analysis
Stock Information
Open
1.10
Close
1.05
High
1.16
Low
1.03
Previous Close
1.15
Daily Price Gain
-0.10
YTD High
1.54
YTD High Date
Jan 10, 2019
YTD Low
0.87
YTD Low Date
Feb 19, 2019
YTD Price Change
-0.15
YTD Gain
-12.50%
52 Week High
7.84
52 Week High Date
Mar 26, 2018
52 Week Low
0.57
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-3.21
52 Week Gain
-75.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 22. 2017
10.00
Apr 3. 2017
12.81
8 Trading Days
28.13%
Link
LONG
Jan 11. 2018
1.44
Feb 13. 2018
3.12
22 Trading Days
117.05%
Link
LONG
Feb 20. 2018
3.29
Mar 7. 2018
5.24
11 Trading Days
59.01%
Link
LONG
Mar 15. 2018
5.44
Mar 28. 2018
6.17
9 Trading Days
13.42%
Link
LONG
Sep 25. 2018
2.11
Oct 8. 2018
2.60
9 Trading Days
23.30%
Link
LONG
Dec 27. 2018
1.00
Jan 22. 2019
1.34
16 Trading Days
34.16%
Link
Company Information
Stock Symbol
AKER
Exchange
NasdaqCM
Company URL
http://www.akersbio.com
Company Phone
856-848-8698
CEO
John J. Gormally
Headquarters
New Jersey
Business Address
201 GROVE RD, THOROFARE, NJ 08086
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Instruments & Supplies
CIK
0001321834
About

Akers Biosciences, Inc. is the developer of health information technologies. It engages in the developing, manufacturing, and supplying screening and testing products to deliver healthcare information to consumers and healthcare providers. Its products include clinical diagnostics, safety diagnostics, wellness products, and tests in development. The company was founded by Raymond Francis Akers, Jr. and Raymond F. Akers, Sr. on March 8, 1989 and is headquartered in West Deptford, NJ.

Description

Akers Biosciences, Inc., together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the United States and internationally. The company offers BreathScan/CHUBE, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor weight loss; VIVO for the measurement of biological markers for oxidative stress that relates to cellular damage non-invasively; PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid assay for detecting heparin-induced thrombocytopenia antibodies; seraSTAT, a device to separate rapid blood cells; and Tri-Cholesterol Check' to estimate high density lipoprotein cholesterol and low density lipo protein levels. It is also involved in the development of Breath Ketone Check', a disposable breath ketone device for diabetic monitoring, and management of senile dementia and alzheimers disease patients; Breath PulmoHealth Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; and PIFA PLUSS that provides rapid tests for various infectious diseases. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.